NCT05387044Unknown2 期
An Open-label, Phase II Single Arm Trial of SBRT for Oligoprogressive NSCLC After First Line Treatment With Immune Checkpoint Inhibitors
适应症
干预措施
试验速览
- 阶段
- 2 期
- 入组人数
- 28
- 试验地点
- 1
- 主要终点
- Progress free survival
研究概览
简要总结
The treatment modality with immunotherapy has been the first-line standard treatment for advanced NSCLC. But more than 2/3 patients still develop acquired drug resistance within 5 years of immunotherapy, and more than 1/2 patients are oligoprogressive. Stereotactic body radiation therapy (SBRT) plays a growing role in the management of oligometastatic disease. This study aims to evaluate the efficacy and safety of SBRT for oligoprogressive NSCLC after first line treatment with immune checkpoint inhibitors.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age at least 18 years;
- •ECOG PS 0-1;
- •Patients with pathologically confirmed stage IV NSCLC by tumor biopsy and/or fine-needle aspiration （AJCC the 8th Edition）;
- •Stable Disease for at least 6 months after first line immunotherapy;
- •Oligoprogressive disease in 5 or fewer lesions and 3 or fewer organs;
- •All oligopreogressive lesion ≤ 5cm, and intracranial lesion ≤3cm or 30cc;
- •Progressive disease would be amenable to SBRT and without indications for palliative radiotherapy in the opinion of the investigator;
- •Patients with a history of radiotherapy are eligible if radiotherapy administered more than 4 weeks before study entry;
- •Adequate organ function prior to enrollment:
- •Adequate bone marrow function: white blood cell (WBC) count ≥ 3.0 * 10 ^ 9/L or neutrophil count ≥ 1.5 * 10 ^ 9/L, platelet count ≥ 100 * 10 ^ 9/L and hemoglobin ≥90g/L,; Adequate hepatic function: total bilirubin, urea nitrogen and serum creatinine≤ 1.5 x upper limit of normal (ULN). Aspartate aminotransferase (AST) and Alanine aminotransferase (ALT) ≤2.0 ULN;
- •Life expectancy of more than 3 months;
- •Ability to understand and willingness to provide the informed consent and signed informed consent for the use of fresh tumor biopsies before and during the treatment;
- •Women of childbearing age and men must agree to use effective contraception during the trial.
排除标准
- •History of another malignancy or concurrent malignancy (except for cured non-melanoma skin cancer, low-risk prostate cancer, T1/T2 glottic cancer, stage 0 or I breast cancer, non-invasive bladder cancer, cervical cancer in situ);
- •Positive for driver genes including EGFR, ALK, and ROS-1;
- •Mixed small cell with non-small cell lung cancer histology;
- •Malignant pleural or ascites;
- •Patients with brain metastasis require intracranial decompression;
- •Symptoms of spinal cord compression;
- •Severe autoimmune disease: inflammatory bowel disease (including Crohn's disease and ulcerative colitis), rheumatoid arthritis, scleroderma, systemic lupus erythematosus, Wegener's granulomatosis and related vasculitides;
- •Symptomatic interstitial lung disease or clinically active infectious/non-infectious pneumonitis.
- •History of another malignancy or concurrent malignancy;
- •Active infection, congestive heart failure, or any evidence of myocardial infarction, unstable angina pectoris or cardiac arrhythmia within 6 months prior to enrollment;
- •The patient is pregnant (confirmed by serum b-HCG if applicable) or is breastfeeding;
- •Mental disorders, drug abuse, and social condition that may negatively impact compliance in the investigator's opinion.
研究组 & 干预措施
SBRT
Experimental
Patients with oligoprogressive NSCLC after first line treatment with immune checkpoint inhibitors will be treated with SBRT for all progressing lesions.
干预措施: SBRT (Radiation)
结局指标
主要结局
Progress free survival
时间窗: two years
PFS was defined from the date of enrollment to the date of disease progression
次要结局
- Grade 3 or higher toxicity(two years)
- Overall survival(two years)
- Time to new metastasis(2 years)
研究者
Xiaojing Lai
Clinical Professor
Zhejiang Cancer Hospital
研究点 (1)
Loading locations...
相似试验
Unknown
1 期
Combining SBRT and Immunotherapy in Early Stage NSCLC Patients Planned for SurgeryNSCLC, Stage INCT03446911Amsterdam UMC, location VUmc20
已完成
2 期
Phase II Trial of Combination Immunotherapy With NeuVax and Trastuzumab in High-risk HER2+ Breast Cancer PatientsBreast CancerNCT02297698Cancer Insight, LLC100
已完成
2 期
Anti-idiotype 1E10 vaccine in advanced non- small cell lung (NSCLC) patientsAdvanced Lung Cancer Non-small Cell Lung CancerCarcinoma, Non-Small-Cell LungCarcinoma, BronchogenicBronchial NeoplasmsLung NeoplasmsRespiratory Tract NeoplasmsThoracic NeoplasmsLung DiseasesRespiratory Tract DiseasesRPCEC00000009Center of Molecular Immunology (CIM)176
招募中
2 期
Intra-arterial Chemotherapy Combined with Radiotherapy and Immunotherapy for HNSCCHead and Neck Squamous Cell CarcinomaNCT06725498Beijing Tongren Hospital50
已完成
不适用
Phase II trial of S-1 therapy for advanced or recurrent esophageal cancer resistant or intolerable existing treatmentsesophageal cancerJPRN-UMIN000023736Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine50